Inventor

Jun Ma

Inventor

Belmont, MA, US

Overview

2014–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 21 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds31%

A61KPreparations for medical, dental or toiletry purposes25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations13%

C07HSugars6%

C07KPeptides4%

B01DSeparation2%

B01JChemical or physical processes, e.g. catalysis or colloid chemistry2%

C02FTreatment of water, waste water, sewage, or sludge2%

C07CAcyclic or carbocyclic compounds2%

G06FElectric digital data processing2%

PatentTitleYear

11,062,176Object detection and image cropping using a multi-detector approach2021 10,829,486Isoxazole derivatives as FXR agonists and methods of use thereof2020 10,689,391Isoxazole analogs as FXR agonists and methods of use thereof2020 10,683,279Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof2020 10,597,391Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof2020 10,450,306Isoxazole analogs as FXR agonists and methods of use thereof2019 10,450,301Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof2019 10,253,018Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof2019 10,246,439Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof2019 10,149,835Isoxazole derivatives as FXR agonists and methods of use thereof2018 10,144,729Isoxazole analogs as FXR agonists and methods of use thereof2018 10,138,228Isoxazole derivatives as FXR agonists and methods of use therof2018 10,080,742Isoxazole derivatives as FXR agonists and methods of use thereof2018 10,080,743Isoxazole derivatives as FXR agonists and methods of use thereof2018 10,080,741Isoxazole derivatives as FXR agonists and methods of use thereof2018 10,034,8935, 6-D2018 9,220,748'Macrocyclic proline derived HCV serine protease inhibitors'2015 9,162,905'Anti-pollution electrocatalysis composite membrane and membrane reactor'2015 9,085,599'2â€²allene-substituted nucleoside derivatives'2015 8,846,638'Macrocyclic nucleoside phosphoramidate derivatives'2014 8,648,037'Macrocyclic proline derived HCV serine protease inhibitors'2014

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2014–2020Patents assigned to ENANTA PHARM INC (19)· patent assignee history

2014–2015Patents assigned to MA JUN (3)· patent assignee history

2014–2015Patents assigned to LONG JIANG (2)· patent assignee history

2014–2015Patents assigned to OR YAT SUN (2)· patent assignee history

2014–2015Patents assigned to WANG GUOQIANG (2)· patent assignee history

2014–2020Based in Belmont, MA, US· patent location history

2015Based in Tianjin, CN· patent location history

2021Based in San Diego, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ENANTA PHARM INC	19	2014–2020
MA JUNself	3	2014–2015
LONG JIANG	2	2014–2015
OR YAT SUN	2	2014–2015
WANG GUOQIANG	2	2014–2015

Locations

Location	Patents	Span
Belmont, Massachusetts, US	19	2014–2020
San Diego, California, US	1	2021
Tianjin, CN	1	2015